PRADEEP ALBERTLegislative development
Antigua & Eastern Caribbean
Contributed to drafting and implementing biotechnology and regenerative medicine legislation in the region.
REGENERATIVE MEDICINE / POLICY / PATIENT SAFEGUARDS
SCIENCE.
STANDARDS.
PUBLIC POLICY.
An overview of selected stem-cell laws and regulatory frameworks, alongside Dr. Pradeep Albert’s contributions to legislative development, expert testimony and policy advisory work.
Sources reviewed September 9, 2026 · Selected jurisdictions, not a comprehensive legal survey.
LEGISLATIVE & ADVISORY WORK
Bringing a clinical perspective to policy.
Professional history supplied by Dr. Albert through his CV and direct updates. These descriptions identify his contributions; they do not imply government endorsement or sole authorship of legislation.
Legislative development
Florida
Helped formulate initial regenerative medicine legislation.
Expert testimony · 2026
Arizona
Provided expert testimony to the Senate Health & Human Services Committee regarding SB 1214 and safeguards for stem-cell and birth-tissue therapies. The bill was subsequently vetoed.
Advisory work
The Bahamas
Advisory work concerning regenerative medicine policy.
Policy engagement
Bahrain
Regenerative medicine policy work in Bahrain. Specific projects and responsibilities are to be detailed.
Policy engagement
Puerto Rico
Regenerative medicine policy work in Puerto Rico. Specific projects and responsibilities are to be detailed.
LAWS & REGULATORY FRAMEWORKS
A landscape with important distinctions.
An enacted law, a proposed bill, a research authorization and an approved medical product are different things. The entries below identify what each linked official source establishes.
Federal framework
United States
FDA oversightStart with the federal requirements
The FDA framework addresses human cells, tissues, and cellular and tissue-based products. Product classification and the applicable pathway matter: state permission, facility registration, or a trial listing does not itself establish FDA approval.
U.S. states
Florida
Enacted statuteFlorida Statutes § 458.3245
Florida establishes a conditional pathway for physicians to provide certain non-FDA-approved stem-cell therapies related to orthopedics, wound care, or pain management. The statute includes sourcing, viability, disclosure and consent requirements. It does not confer FDA approval or remove applicable federal obligations.
Arizona
Vetoed · June 19, 2026SB 1214 · 2026 legislative session
The proposal addressed stem-cell and birth-tissue therapies and related safeguards. Governor Katie Hobbs vetoed SB 1214 on June 19, 2026. It should not be represented as an enacted authorization for treatment.
U.S. territories
Puerto Rico
Federal baselineFederal requirements remain relevant
Puerto Rico is not an exemption from U.S. federal regulation of regenerative medicine products. Review the FDA pathway alongside applicable local professional and facility requirements. This guide does not establish a separate Puerto Rico treatment authorization.
U.S. Virgin Islands & Guam
Federal baselineTerritorial location is not product approval
Federal food and drug law expressly addresses territories. A territorial location should not be treated as permission to bypass applicable federal requirements. Territory-specific licensing and local legislation are outside this overview and require separate review.
Countries
Antigua & Barbuda
Published legislationStem Cell Research and Therapy Act, 2019
The Act provides a framework for oversight of stem-cell research and therapy, including licensing of laboratories and research facilities, inspections, and prohibited procedures. A legislative framework is not blanket approval of every therapy or provider.
The Bahamas
Published legislationLongevity and Regenerative Therapies Act, 2024
The 2024 Act sets out a national framework for approval and regulation of longevity and regenerative therapies. It establishes a board and ethics review committee, with provisions for applications, approvals, monitoring and licensing. Readers should consult this newer framework rather than relying solely on the 2013 Stem Cell Act.
Bahrain
Clinical research frameworkNational Health Regulatory Authority
The NHRA regulates, authorizes and oversees clinical research and trials, including ethical and scientific review requirements. This source describes research oversight; it does not establish general permission for commercial stem-cell treatment. A current stem-cell-specific enactment has not been verified for this guide.